26,651 Shares in Grail, Inc. (NASDAQ:GRAL) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new position in Grail, Inc. (NASDAQ:GRAL - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 26,651 shares of the company's stock, valued at approximately $476,000. Raymond James Financial Inc. owned approximately 0.08% of Grail as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of Grail in the fourth quarter worth about $244,000. Moloney Securities Asset Management LLC purchased a new position in Grail during the 4th quarter valued at approximately $559,000. Rhumbline Advisers bought a new stake in Grail in the 4th quarter worth approximately $456,000. Wesbanco Bank Inc. purchased a new stake in shares of Grail during the 4th quarter worth approximately $523,000. Finally, Slow Capital Inc. bought a new position in shares of Grail during the 4th quarter valued at approximately $2,379,000.

Insider Activity at Grail

In other Grail news, CEO Robert P. Ragusa sold 7,625 shares of the business's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $31.21, for a total transaction of $237,976.25. Following the transaction, the chief executive officer now owns 828,662 shares in the company, valued at $25,862,541.02. The trade was a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Aaron Freidin sold 1,816 shares of the firm's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $31.20, for a total transaction of $56,659.20. Following the completion of the sale, the chief financial officer now owns 335,170 shares of the company's stock, valued at $10,457,304. This trade represents a 0.54 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,550 shares of company stock worth $360,436.

Remove Ads

Analyst Upgrades and Downgrades

Separately, Morgan Stanley boosted their price target on shares of Grail from $16.00 to $20.00 and gave the stock an "equal weight" rating in a research report on Tuesday, March 18th.

Grail Stock Up 2.2 %

Shares of NASDAQ GRAL traded up $0.51 during mid-day trading on Friday, hitting $23.26. 1,024,682 shares of the company's stock traded hands, compared to its average volume of 1,226,001. Grail, Inc. has a 1 year low of $12.33 and a 1 year high of $63.99. The company's 50-day moving average is $33.52 and its two-hundred day moving average is $23.27.

Grail (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.41) by $2.55. The company had revenue of $38.25 million for the quarter, compared to analysts' expectations of $35.33 million. On average, equities research analysts anticipate that Grail, Inc. will post -15.15 EPS for the current fiscal year.

Grail Profile

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.